Abstract
In 1997, knowledge about the treatment of autoimmune rheumatic diseases increased further. The most promising data to date came from studies using tumor necrosis factor-alpha blocking agents, such as monoclonal antibodies or soluble receptor constructs. Clinical trials with these compounds have now advanced to phase III; however, long-term safety data are not yet available. In addition, new developments with regard to T-helper cell-directed treatment principles, anti-inflammatory cytokines, and adhesion molecules are discussed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
